Fintel reports that on November 14, 2024, Citigroup initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Buy ...

Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Gilead’s bread and butter has been ...

Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over ...

Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to ...

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Gilead Sciences (GILD) closed the most recent trading day at $88.82, moving +0.6% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 1.86% for the day.

STAT+ subscribers can sign up here to get it delivered to their inbox. The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.

Gilead Sciences (GILD) closed the latest trading day at $87.23, indicating a -1.05% change from the previous session's end. This move lagged the S&P 500's daily loss of 0.92%. Meanwhile ...

The treatment combines MSD’s islatravir with Gilead’s lenacapavir. Credit: Ground Picture via Shutterstock. Gilead Sciences and MSD are advancing their once-weekly HIV treatment regimen to Phase II ...